1706O Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase III COMPETE trial.
Saved in:
| Title: | 1706O Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with grade 1 or grade 2 GEP-NETs: Phase III COMPETE trial. |
|---|---|
| Authors: | Capdevila, J.1 (AUTHOR), Amthauer, H.2 (AUTHOR), Ansquer, C.3 (AUTHOR), Deshayes, E.4 (AUTHOR), Garcia-Carbonero, R.5 (AUTHOR), Teule, A.6 (AUTHOR), Verberne, H.J.7 (AUTHOR), Cwikla, J.B.8 (AUTHOR), Sri Rajaskanthan, R.9 (AUTHOR), Grana, C.M.10 (AUTHOR), Baum, R.P.11 (AUTHOR), Dierickx, L.O.12 (AUTHOR), Michael, M.13 (AUTHOR), Strosberg, J.R.14 (AUTHOR), de Mestier du Bourg, L.15 (AUTHOR), Kluge, A.16 (AUTHOR), Melnyk, S.17 (AUTHOR), Walter, T.18 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1006-S1006. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.2334 |
